Claire Falandry

5.3k total citations · 1 hit paper
109 papers, 3.1k citations indexed

About

Claire Falandry is a scholar working on Oncology, Geriatrics and Gerontology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Claire Falandry has authored 109 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 33 papers in Geriatrics and Gerontology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Claire Falandry's work include Frailty in Older Adults (28 papers), Cancer Treatment and Pharmacology (22 papers) and Nutrition and Health in Aging (14 papers). Claire Falandry is often cited by papers focused on Frailty in Older Adults (28 papers), Cancer Treatment and Pharmacology (22 papers) and Nutrition and Health in Aging (14 papers). Claire Falandry collaborates with scholars based in France, United States and Italy. Claire Falandry's co-authors include Gilles Freyer, Étienne Brain, Lazzaro Repetto, Hans Wildiers, Eva Topinková, Koen Milisen, Arti Hurria, Andrew Artz, Johan Flamaing and Riccardo A. Audisio and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Claire Falandry

102 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer

2014 1.2k citations Claire Falandry et al. profile →

Peers

Countries citing papers authored by Claire Falandry

Since Specialization

Citations

This map shows the geographic impact of Claire Falandry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Falandry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Falandry more than expected).

Fields of papers citing papers by Claire Falandry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Falandry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Falandry. The network helps show where Claire Falandry may publish in the future.

Co-authorship network of co-authors of Claire Falandry

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Falandry. A scholar is included among the top collaborators of Claire Falandry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Falandry. Claire Falandry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enhancing collaboration between geriatricians, oncologists, and pharmacists to optimize medication therapy in older adults with cancer: A position paper from SOFOG-SFPO 2023 ·Critical Reviews in Oncology/Hematology ·(unknown), (unknown), (unknown), Mathieu Boulin, Claire Falandry, Laure de Decker, Catherine Rioufol, Arnaud Bayle, Nicolas Bertrand	5
2	Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database 2023 ·Drugs & Aging ·(unknown), Maël Heiblig, Gilles Freyer, Hervé Ghesquières, Claire Falandry	2
3	Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study 2022 ·The Lancet Healthy Longevity ·Claire Falandry, Fanny Pommeret, Laurence Gladieff, Fabien Tinquaut, Domenica Lorusso, Marie‐Ange Mouret‐Reynier, Véronique D’Hondt, (unknown), Anne Floquet, Sophie Abadie‐Lacourtoisie, Pierre-Emmanuel Brachet, Laëtitia Stefani, Frédérique Rousseau, Jean‐Sébastien Frenel, Francesco Del Piano, Marja Komulainen, (unknown), Olivier Trédan, Éric Pujade-Lauraine, Gilles Freyer	7
4	Senior-COVID-Rea Cohort Study: A Geriatric Prediction Model of 30-day Mortality in Patients Aged over 60 Years in ICU for Severe COVID-19 2022 ·Aging and Disease ·Claire Falandry, Laurent Bitker, Paul Abraham, Fabien Subtil, (unknown), Baptiste Balança, (unknown), Céline Guichon, Christophe Leroy, Marie Simon, (unknown), Jean‐Baptiste Pialat, Laurent Jallades, Alain Lepape, Arnaud Friggeri, Fabrice Thiollière	1
5	Screening for hypertension-mediated organ damage and aetiology: Still of value after 65 years of age? 2021 ·Archives of Cardiovascular Diseases Supplements ·(unknown), (unknown), Brahim Harbaoui, (unknown), Claire Falandry, Pierre Lantelme, Pierre‐Yves Courand	1
6	Challenges with the management of older patients with cancer during the COVID-19 pandemic 2020 ·Journal of Geriatric Oncology ·Claire Falandry, (unknown), (unknown), Olivia Le Saux	15
7	Therapeutic management and outcome of nonagenarians versus octogenarians admitted to an intensive care unit for acute coronary syndromes 2020 ·Archives of cardiovascular diseases ·(unknown), (unknown), Brahim Harbaoui, Claire Falandry, Pierre Lantelme, Pierre‐Yves Courand	5
8	Tumeurs épithéliales de l’ovaire : les personnes âgées. Article rédigé sur la base de la recommandation nationale de bonnes pratiques cliniques en cancérologie intitulée « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l’égide du CNGOF et labellisée par l’INCa 2019 ·Gynécologie Obstétrique Fertilité & Sénologie ·Claire Falandry, Sébastien Gouy	3
9	Toxicity of Cancer Therapies in Older Patients 2018 ·Current Oncology Reports ·Olivia Le Saux, Claire Falandry	20
10	Is There an Age Threshold for Holding Off on Testing Novel Therapies? 2018 ·Current Oncology Reports ·Olivia Le Saux, Claire Falandry	1
11	Changes in the use of end points in clinical trials for elderly cancer patients over time 2017 ·Annals of Oncology ·Olivia Le Saux, Claire Falandry, Hui Gan, Benoît You, Gilles Freyer, Julien Péron	19
12	Inclusion of elderly patients in oncology clinical trials 2016 ·Annals of Oncology ·Olivia Le Saux, Claire Falandry, Hui Gan, Benoît You, Gilles Freyer, Julien Péron	67
13	Defining and recognising locally advanced basal cell carcinoma 2015 ·European Journal of Dermatology ·J.-M. Amici, Maxime Battistella, M. Beylot‐Barry, (unknown), (unknown), Brigitte Dréno, Claire Falandry, (unknown), Damien Giacchero, Jean‐Jacques Grob, (unknown), M.‐T. Leccia, O. Malard, Laurent Mortier, Émilie Routier, (unknown), Dinu Stefan, Pierre‐Emmanuel Stoebner, Nicole Basset‐Séguin	23
14	Concomitant drugs with low risks of drug–drug interactions for use in oncology clinical trials 2015 ·Critical Reviews in Oncology/Hematology ·Florence Ranchon, Thierry Vial, Catherine Rioufol, Émilie Hénin, Claire Falandry, Gilles Freyer, V. Trillet-Lenoir, Christophe Le Tourneau, Benoît You	8
15	Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial 2013 ·Annals of Oncology ·Claire Falandry, B. Weber, Aude-Marie Savoye, Fabien Tinquaut, Olivier Trédan, Emmanuel Sevin, Laëtitia Stefani, Francesco Savinelli, (unknown), J Salvat, Éric Pujade-Lauraine, Gilles Freyer	86
16	Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Nicolás Isambert, Gilles Freyer, Sylvie Zanetta, Benoît You, P. Fumoleau, Claire Falandry, Laure Favier, Sylvie Assadourian, Karen Soussan-Lazard, (unknown), V. Trillet-Lenoir	31
17	Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. 2011 ·PubMed ·Gilles Freyer, (unknown), G. Milano, Étienne Chatelut, Christine Rebischung, Jean‐Pierre Delord, Yacine Merrouche, Gérard Lledo, Marie‐Christine Etienne, Claire Falandry	14
18	Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs 2011 ·BMC Cancer ·Florence Ranchon, Gilles Salles, Hans-Martin Späth, Vérane Schwiertz, Nicolas Vantard, Stéphanie Parat, Florence Broussais, Benoît You, Sophie Tartas, P.-J. Souquet, Claude Dussart, Claire Falandry, Émilie Hénin, Gilles Freyer, Catherine Rioufol	93
19	L’évaluation gériatrique est-elle adaptée à la radiothérapie ? 2008 ·Cancer/Radiothérapie ·Claire Falandry, (unknown), F. Mornex, Marc Bonnefoy, Gilles Freyer	2
20	Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK) 2005 ·Annals of Oncology ·Michele Ghielmini, Kaspar Rufibach, Gilles Salles, (unknown), Claire Falandry, Sergio Cogliatti, Martin F. Fey, Giovanni Martinelli, Rolf A. Stahel, Andreas Lohri, Nicolas Ketterer, Martin Wernli, Thomas Cerny, S.‐F. Hsu Schmitz	121

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact